Status:
COMPLETED
A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG
Lead Sponsor:
Mati Therapeutics Inc.
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of two formulations of the Latanoprost-PPDS in subjects with ocular hypertension or open-angle glaucoma.
Eligibility Criteria
Inclusion
- Subjects over 18 years of age diagnosed with ocular hypertension or open-angle glaucoma
- Subjects who have a best corrected visual acuity of 20/100 or better
Exclusion
- Subjects who wear contact lenses
- Subjects who have uncontrolled medical conditions
- Subjects requiring chronic topical artificial tears, lubricants, and/or requiring any other chronic ocular topical medications
- Subjects who have a history of chronic or recurrent inflammatory eye disease
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT00967811
Start Date
August 1 2009
End Date
May 1 2010
Last Update
September 19 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Menlo Park, California, United States, 94025